{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:16:26Z","timestamp":1783664186280,"version":"3.55.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the proven efficacy of KRAS G12C inhibitors (KRAS G12Ci) in solid tumors, evidence from direct comparisons with standard of care is scarce, and no analysis has investigated the potential immunological basis for differential responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Cochrane Library, and ClinicalTrials.gov for randomized controlled trials (RCTs) involving solid tumors patients who had received KRAS G12Ci were retrieved from inception to March 28, 2026. Individual participant data on progression-free survival (PFS) and overall survival (OS) were extracted from the published Kaplan-Meier survival curves. When available, subgroup data by programmed death ligand 1 (PD-L1) expression were extracted to explore immune-related correlates of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 4 articles with 3 RCTs and 949 participants were selected. In 1-stage reconstructed individual patient data meta-analyses, PFS was better in the KRAS G12Ci group (HR, 0.62; 95% CI, 0.53-0.74;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). However, no statistical difference in OS was observed (HR, 0.93; 95% CI, 0.74-1.16;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.495). The results were confirmed by 2-stage meta-analyses which additionally exhibited an objective response rate (ORR) of 3.60 (95% CI; 2.01-6.46;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001; I\n                      <jats:sup>2<\/jats:sup>\n                      = 39.7%). Regarding PD-L1 expression, PFS benefits were observed in patients with expression levels &amp;lt;1% (HR, 0.56; 95% CI: 0.38-0.83;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.004) and 1%-49% (HR, 0.58; 95% CI: 0.43-0.78;\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). KRAS G12Ci demonstrated a better safety profile, apart from diarrhea and rash.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A similar OS, but better PFS and ORR with a superior safety profile were observed in patients receiving KRAS G12Ci, suggesting that KRAS G12Ci may be more suitable for later-line therapy. Older patients, those without liver metastases, or those with PD-L1&amp;lt;50% may be the target population. These subgroup observations are hypothesis-generating and require prospective validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      , identifier CRD420251146769.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1848431","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:29Z","timestamp":1783661909000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS G12C inhibitors in KRASG12C-mutated solid tumors: an immunologically informed systematic review and reconstructed individual patient data meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yici","family":"Yan","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyi","family":"Zheng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leitao","family":"Sun","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]},{"name":"Academy of Chinese Medical Science, Zhejiang Chinese Medical University","place":["Hangzhou, China"]},{"name":"Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Xu","sequence":"additional","affiliation":[{"name":"Pinghu Traditional Chinese Medicine Hospital","place":["JiaXing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120858","article-title":"Personalized therapy for lung cancer: striking a moving target","volume":"3","author":"Pakkala","year":"2018","journal-title":"JCI Insight"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2030638","article-title":"Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.044","article-title":"Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients","volume":"183","author":"Kim","year":"2020","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00256","article-title":"Comprehensive clinical and molecular characterization of KRAS (G12C)-mutant colorectal cancer","volume":"5","author":"Henry","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13046-025-03444-1","article-title":"Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle","volume":"44","author":"Fu","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl6464","article-title":"Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses","volume":"10","author":"Cole","year":"2024","journal-title":"Sci Adv"},{"key":"B9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102070","article-title":"KRAS: from undruggable to a druggable cancer target","volume":"89","author":"Uprety","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(24)00110-3","article-title":"Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial","volume":"12","author":"Li","year":"2024","journal-title":"Lancet Respir Med"},{"key":"B14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/j.jtho.2024.09.074","article-title":"OA14.05 KRAS G12C inhibitor IBI351 in patients (pts) with advanced non-small cell lung cancer (NSCLC): updated results from a pivotal phase 2 study","volume":"19","author":"Zhou","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2308795","article-title":"Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/nejmoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189108","article-title":"Activity and resistance to KRAS(G12C) inhibitors in non-small cell lung cancer and colorectal cancer","volume":"1879","author":"Ye","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1509173","article-title":"Current status of KRAS G12C inhibitors in NSCLC and the potential for combination with anti-PD-(L)1 therapy: a systematic review","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012886","article-title":"Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression","volume":"14","author":"Liu","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102317","article-title":"Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy","volume":"6","author":"Hirade","year":"2025","journal-title":"Cell Rep Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00866-9","article-title":"Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial","volume":"406","author":"Barlesi","year":"2025","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-02026","article-title":"Overall survival analysis of the phase III CodeBreaK 300 study of sotorasib plus panitumumab versus investigator's choice in chemorefractory KRAS G12C colorectal cancer","volume":"43","author":"Pietrantonio","year":"2025","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-20-0462","article-title":"The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy","volume":"20","author":"Briere","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02524","article-title":"Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-year analysis of CodeBreaK 100","volume":"41","author":"Dy","year":"2023","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.036","article-title":"PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice","volume":"160","author":"Kim","year":"2021","journal-title":"Gastroenterology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1186\/s12885-024-12400-9","article-title":"Factors correlating the expression of PD-L1","volume":"24","author":"Lu","year":"2024","journal-title":"BMC Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.504","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","article-title":"Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers","volume":"22","author":"Zhang","year":"2023","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2509012122","article-title":"Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib","volume":"122","author":"Maso","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ccell.2022.07.005","article-title":"A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.066","article-title":"LBA65 KRYSTAL-7: efficacy and safety of adagrasib with pembrolizumab in patients with treatment-na\u00efve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"34","author":"Garassino","year":"2023","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.8519","article-title":"Safety and efficacy of olomorasib + immunotherapy in first-line treatment of patients with KRAS G12C-mutant advanced NSCLC: update from the LOXO-RAS-20001 trial","volume":"43","author":"Dragnev","year":"2025","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aaw9450","article-title":"KRAS(G12C) inhibition produces a driver-limited state revealing collateral dependencies","volume":"12","author":"Lou","year":"2019","journal-title":"Sci Signal"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100131","article-title":"Overcoming adaptive resistance to KRAS and MEK inhibitors by co-targeting mTORC1\/2 complexes in pancreatic cancer","volume":"1","author":"Brown","year":"2020","journal-title":"Cell Rep Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.cd-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov"},{"key":"B46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cells14181413","article-title":"TIMP-1 modulation correlates with KRAS dependency and EMT induction in NSCLC","volume":"14","author":"M-Thirusenthilarasan","year":"2025","journal-title":"Cells"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01099-z","article-title":"Liver, ageing and disease","volume":"22","author":"Le Couteur","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0043","article-title":"NCCN Guidelines\u00ae Insights: Non-small cell lung cancer, Version 7.2025","volume":"23","author":"Riely","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-020-00806-z","article-title":"The interplay between immunosenescence and age-related diseases","volume":"42","author":"Barb\u00e9-Tuana","year":"2020","journal-title":"Semin Immunopathol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41392-023-01451-2","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041197","article-title":"Aging and inflammation","volume":"14","author":"Singh","year":"2024","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:38:31Z","timestamp":1783661911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2026.1848431"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1848431","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"article-number":"1848431"}}